Related Experiment Videos

Pernicious anemia revisited

R K Pruthi1, A Tefferi

  • 1Division of Hematology and Internal Medicine, Mayo Clinic Rochester, MN 55905.

Mayo Clinic Proceedings
|February 1, 1994
PubMed

Insights

Pernicious anemia (PA) is a treatable hematologic disorder. Diagnosis can be challenging, but urinary methylmalonic acid levels offer a practical alternative for detecting cobalamin deficiency.

Area of Science:

  • Hematology
  • Internal Medicine

Background:

  • Pernicious anemia (PA) is a condition affecting various organ systems.
  • Patients may present with diverse symptoms or be asymptomatic.
  • Hematologic parameters can be normal despite cobalamin deficiency.

Purpose of the Study:

  • To review the pathophysiology, clinical presentation, diagnosis, and treatment of PA.
  • To discuss advancements in diagnostic and therapeutic approaches for PA.

Main Methods:

  • Literature review focusing on clinical applications and progress in PA diagnosis and treatment.
  • Evaluation of diagnostic methods for cobalamin deficiency, including urinary methylmalonic acid and the Schilling test.

Main Results:

  • Lifelong vitamin B12 therapy is essential for managing PA.
  • Intramuscular administration is the customary route for vitamin B12, though alternatives exist.
  • Urinary methylmalonic acid is a potentially more sensitive and practical diagnostic marker.

Conclusions:

  • Pernicious anemia is a highly treatable hematologic condition.
  • Early and accurate diagnosis is crucial for effective management.
Abstract

Related Concept Videos